European Pharmaceutical Review

JANUARY 23, 2025

For instance, patent expiries are set to wipe out $300 billion in revenues by 2028. 4 Looking ahead, China is becoming an increasingly important research and development (R&D) target for companies seeking to license-in antibody-drug conjugates (ADCs) and other novel oncology treatments. EY (Ernst & Young). cited 2025Jan].

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration 59

Food and Drug Administration Sales FDA Marketing 59

Pharmaceutical Technology

NOVEMBER 8, 2022

Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration 59

Food and Drug Administration Leads Food Pharma 59

European Pharmaceutical Review

MAY 2, 2023

billion in 2028, according to GlobalData’s Pharma Intelligence Center. Limiting progression of geographic atrophy via C5 inhibition Specifically, ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base, according to Astellas.

Food and Drug Administration 52

Food and Drug Administration Pharma Sales FDA 52

Pharmaceutical Technology

MARCH 30, 2023

The drug is approved in several indications, including advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and relapsed classical Hodgkin lymphoma (cHL). As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028. billion in 2028.

Food and Drug Administration 52

Food and Drug Administration FDA Sales Food 52

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98